Through the agreement, BMS will supply its best-selling cancer drug Opdivo for Bavarian Nordic to use in a clinical trial.
The study, expected to include around 160 patients, will examine the efficacy of combining its drug CV301 with Opdivo in patients with previously untreated non-small cell lung cancer.
Bavarian Nordic will maintain all commercial rights for CV301.
The study is expected to start later this year.
More articles on the drug market:
Secretive board at Express Scripts determines drug exclusions
Aurobindo Pharma to open vaccine manufacturing facility
Lethal drug poses new threat to the opioid epidemic
